ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,156 GBX | -0.12% |
|
+7.88% | +14.68% |
| 05:18pm | AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial | MT |
| 04:46pm | AstraZeneca: research into respiratory diseases | CF |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 236B | ||||||
| 699B | ||||||
| 571B | ||||||
| 364B | ||||||
| 326B | ||||||
| 286B |
- Stock Market
- Equities
- AZN Stock
- Charts AstraZeneca PLC
- Sector Chart
